Doxazosin inhibits vasculogenic mimicry in human non ‑small cell lung cancer through inhibition of the VEGF‑A/VE‑cadherin/mTOR/MMP pathway

In conclusion, the present study demonstrated that doxazosin displayed anti-VM activity in an NSCLC cell model through the downregulation of VEGF-A and VE-cadherin levels, and the suppression of signaling pathways related to the receptor tyrosine kinase, EphA2, protein kinases, AKT and mTOR, and proteases, MMP-2 and MMP-9. These results support the add-on anti-VM effect of doxazosin as a potential agent against NSCLC.PMID:38455663 | PMC:PMC10918514 | DOI:10.3892/ol.2024.14303
Source: Oncology Letters - Category: Cancer & Oncology Authors: Source Type: research